Intellia Therapeutics Inc. (NASDAQ:NTLA) went down by -4.89% from its latest closing price compared to the recent 1-year high of $155.63. The company’s stock price has collected -6.90% of loss in the last five trading sessions. The Wall Street Journal reported on 09/16/22 that Crispr Gene-Editing Drugs Show Promise in Preliminary Study
Is It Worth Investing in Intellia Therapeutics Inc. (NASDAQ :NTLA) Right Now?
Plus, the 36-month beta value for NTLA is at 1.99.
NTLA currently public float of 68.62M and currently shorts hold a 10.02% ratio of that float. Today, the average trading volume of NTLA was 1.30M shares.
NTLA’s Market Performance
NTLA stocks went down by -6.90% for the week, with a monthly jump of 9.62% and a quarterly performance of 30.59%, while its annual performance rate touched -59.75%. The volatility ratio for the week stands at 8.97% while the volatility levels for the past 30 days are set at 7.08% for Intellia Therapeutics Inc. The simple moving average for the period of the last 20 days is -3.44% for NTLA stocks with a simple moving average of -16.68% for the last 200 days.
Analysts’ Opinion of NTLA
Many brokerage firms have already submitted their reports for NTLA stocks, with JP Morgan repeating the rating for NTLA by listing it as a “Overweight.” The predicted price for NTLA in the upcoming period, according to JP Morgan is $85 based on the research report published on September 21st of the current year 2022.
Citigroup, on the other hand, stated in their research note that they expect to see NTLA reach a price target of $50. The rating they have provided for NTLA stocks is “Sell” according to the report published on September 01st, 2022.
BMO Capital Markets gave a rating of “Market Perform” to NTLA, setting the target price at $54 in the report published on June 17th of the current year.
NTLA Trading at -5.73% from the 50-Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.79% of loss for the given period.
Volatility was left at 7.08%, however, over the last 30 days, the volatility rate increased by 8.97%, as shares sank -1.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.56% lower at present.
During the last 5 trading sessions, NTLA fell by -6.90%, which changed the moving average for the period of 200-days by -41.14% in comparison to the 20-day moving average, which settled at $61.54. In addition, Intellia Therapeutics Inc. saw -49.70% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at NTLA starting from LEONARD JOHN M, who sale 2,493 shares at the price of $112.25 back on Jan 01. After this action, LEONARD JOHN M now owns 724,660 shares of Intellia Therapeutics Inc., valued at $279,852 using the latest closing price.
Goddard Glenn, the EVP, Chief Financial Officer of Intellia Therapeutics Inc., sale 1,013 shares at $112.24 during a trade that took place back on Jan 01, which means that Goddard Glenn is holding 2,049 shares at $113,699 based on the most recent closing price.
Stock Fundamentals for NTLA
Current profitability levels for the company are sitting at:
- -810.37 for the present operating margin
- +79.15 for the gross margin
The net margin for Intellia Therapeutics Inc. stands at -810.49. Equity return is now at value -40.20, with -32.40 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.11.